Matches in Ubergraph for { <https://frink.apps.renci.org/.well-known/genid/B399d16fc0f0acf7fa33cb030ef7eff8d> ?p ?o ?g. }
Showing items 1 to 5 of
5
with 100 items per page.
- B399d16fc0f0acf7fa33cb030ef7eff8d NCIT_P378 "NCI" @default.
- B399d16fc0f0acf7fa33cb030ef7eff8d type Axiom @default.
- B399d16fc0f0acf7fa33cb030ef7eff8d annotatedProperty IAO_0000115 @default.
- B399d16fc0f0acf7fa33cb030ef7eff8d annotatedSource NCIT_C102754 @default.
- B399d16fc0f0acf7fa33cb030ef7eff8d annotatedTarget "An orally available small molecule inhibitor of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK) with potential antineoplastic activity. Upon oral administration, ensartinib binds to and inhibits ALK kinase, ALK fusion proteins and ALK point mutation variants. Inhibition of ALK leads to the disruption of ALK-mediated signaling and eventually inhibits tumor cell growth in ALK-expressing tumor cells. ALK belongs to the insulin receptor superfamily and plays an important role in nervous system development. ALK is not expressed in healthy adult human tissue but ALK dysregulation and gene rearrangements are associated with a series of tumors; ALK mutations are associated with acquired resistance to small molecule tyrosine kinase inhibitors." @default.